CureVac N.V. (BIT:1CVAC)

Market Cap	968.75M
Revenue (ttm)	70.74M
Net Income (ttm)	128.82M
Shares Out	n/a
EPS (ttm)	0.80
PE Ratio	7.52
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	115
Open	n/a
Previous Close	4.492
Day's Range	n/a
52-Week Range	2.146 - 4.936
Beta	n/a
RSI	39.47
Earnings Date	Apr 24, 2026

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). The company’s portfolio includes clinical and preclinical candidates for various disease indications in prophylactic vaccines, oncology, and molecular therapy. It also delivers optimized mRNAs to stimulate the production of therapeutic proteins utilizing its technology and instructs human cells to produce or secrete specific proteins in the nucleus, cytoplasm, cellular organelles, and cell membrane. In ad...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 983
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1CVAC